作者
B Kiesewetter, U Dafni, EGE de Vries, Jorge Barriuso, G Curigliano, Verónica González-Calle, M Galotti, B Gyawali, BJP Huntly, U Jäger, NJ Latino, L Malcovati, SF Oosting, G Ossenkoppele, M Piccart, M Raderer, L Scarfò, D Trapani, CC Zielinski, R Wester, P Zygoura, E Macintyre, NI Cherny, ESMO-MCBS Working Group, Extended Working Group
发表日期
2023/9/1
期刊
Annals of Oncology
卷号
34
期号
9
页码范围
734-771
出版商
Elsevier
简介
Background
The European Society for Medical Oncology (ESMO)-Magnitude of Clinical Benefit Scale (MCBS) has been accepted as a robust tool to evaluate the magnitude of clinical benefit reported in trials for oncological therapies. However, the ESMO-MCBS hitherto has only been validated for solid tumours. With the rapid development of novel therapies for haematological malignancies, we aimed to develop an ESMO-MCBS version that is specifically designed and validated for haematological malignancies.
Methods
ESMO and the European Hematology Association (EHA) initiated a collaboration to develop a version for haematological malignancies (ESMO-MCBS:H). The process incorporated five landmarks: field testing of the ESMO-MCBS version 1.1 (v1.1) to identify shortcomings specific to haematological diseases, drafting of the ESMO-MCBS:H forms, peer review and revision of the draft based on re …
学术搜索中的文章
B Kiesewetter, U Dafni, EGE de Vries, J Barriuso… - Annals of Oncology, 2023